DESCRIPTION (provided by applicant): This grant application is by Ion Channel Innovations, LLC, (ICI) a company dedicated to the development of naked DNA transfer to treat the unmet needs of people with common smooth muscle diseases that negatively impactthe quality of life of millions.

This study is a double-blind, placebo controlled, parallel design, Phase 2A study evaluating the potential activity and safety of a single administration of hMaxi-K (8000 or 16000 µg) or placebo (PBS sucrose 20%) injected into the corpus cavernosum of the penis in men who have been unable to tolerate, do not wish to continue, or have had unsuccessful results with, prior therapy for ED. Participants received a single injection of hMaxi-K 8000 micrograms (µg) into the corpus cavernosum of the penis. Participants received a single injection of hMaxi-K 16000 µg into the corpus cavernosum of the penis. Participants received a single injection of matching placebo (PBS-20% sucrose) into the corpus cavernosum of the penis. May 15, 2008 · Maxi-K gene therapy may be a safe and effective future option for men whose erectile dysfunction is not treatable with oral therapy. Maxi-K therapy is a unique, locally administrated gene-transfer hMaxi-K gene therapy - Sumitovant Biopharma Alternative Names: hMaxi-K - Ion Channel Innovations; hMaxi-K; pVAX/hSlo; URO-902 Latest Information Update: 06 Feb 2020 Patients given tlie two highest doses of hMaxi-K had apparent sustained improvements in erectile function (EF) as indicated by improved HEF-EF domain scores over the length of the study. One Jan 16, 2020 · Evaluating the safety and potential activity of URO‐902 (hMaxi‐K) gene transfer by intravesical instillation or direct injection into the bladder wall in female participants with idiopathic (non‐neurogenic) overactive bladder syndrome and detrusor overactivity from two double‐blind, imbalanced, placebo‐controlled randomized phase 1 trials

This gene therapy involves injection of a transfer gene, calcium-sensitive potassium channel (hMaxi-K), into the penis. They compare sleep to overeating. During patient interviews, doctors try to answer the following questions:1. And walked away with WONDERFUL images. Staff pitched their "secret formula" as safer and more effective than drugs.

Urovant Sciences Ltd. UROV,a clinical-stage biopharmaceutical company focused on developing therapies for urologic conditions, today reported financial

39. Melman A, Davies K, McCullough A, Bar-Chama N, Christ G. Long-term safety follow-up of a phase 1 trial for gene transfer therapy of ED with hMaxi-K. J Urol. 2008;179(suppl 4):426. 40. Payne RE, Sadovsky R. Identifying and treating premature ejaculation: importance of the sexual history. Cleve Clin J Med. 2007;74(suppl 3):S47-S53. 41.

September 30, 2018 March 31, 2018 Assets (Note 2) Current assets: Cash $ 1,659 $ 7,194 Nov 12, 2018 · Urovant has licensed global rights, excluding Japan and certain Asian territories, for the development and commercialization of vibegron. Urovant’s second product candidate, hMaxi-K, is a novel gene therapy being developed for patients with OAB who have failed oral pharmacological therapy.